68Ga-DOTA-TATE PET-CT comparison with 99mTc-HYNIC-TOC SPECT-CT in the assessment of the extent of the disease in patients with malignant endocrine tumors: our experience (preliminary results) Abstract #115

Introduction: In neuroendocrine tumors (NETs), the workup is often difficult not only to visualize but also to co-localize the lesions anatomically. Liver and bones are one of the most frequent sites of metastases in patients with endocrine tumors. The Tyr3-octreotate (TATE) somatostatin analogue differs from TOC in that the terminal threonine replaces threoninol. The terminal threonine results in a higher receptor binding (mainly subtype 2) and better internalisation, with the consequence that tumor uptake of the tracer is intense.
Aim(s): To evaluate the diagnostic value of 68Ga-DOTA-TATE PET-CT comparison with 99mTc-HYNIC-TOC SPECT-CT in the assessment of disease extent in patients with malignant neuroendocrine tumors in our institution.
Materials and methods: 68Ga-DOTA-TATE PET-CT and 99mTc-HYNIC-TOC SPECT/CT studies were performed in nine patients. The interval time between of these two studies was 2 – 28 weeks. Conventional scintigraphy was acquired on the hybrid gamma camera SPECT/CT in 2-4 h after intravenous injection of 99mTc-HYNIC-TOC. The injected activity was 550-740 MBq (15-20mCi). The following views were gathered: planar AP, PA and SPECT/CT of the chest and abdomen. PET-CT scans were acquired 45 – 60 min postinjection of 120 – 200 MBq (3.5 – 5.5 mCi) of 68Ga-DOTA-TATE. Data acquisition was performed with a 15-cm axial field of view (FOV) and 55-cm transaxial FOV PET-CT scanner. Patients were imaged in 3-dimensional mode with the duration of acquisition 3 - 5 min per bed position in emission mode.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: MD, PhD Norbert Szalus

To read results and conclusion, please login ...

Further abstracts you may be interested in

#867 Mixed Adenoneuroendocrine Carcinoma (MANECs): A Rare and Challenging Subgroup of Neuroendocrine Neoplasia
Introduction: Mixed Adenoneuroendocrine Carcinomas (MANECs) are rare entities in which at least 30% of neoplastic cells are neuroendocrine in nature (WHO 2010 classification). They result either from two independent lesions that merge together or are unique lesions with different cell populations intermingled.
Conference: 11th Annual ENETS Conference (2014)
Category: Pathology, grading, staging
Presenting Author: Dr Conor Mosli Lynch
#2250 Treatment Outcomes of Patients with Mixed Neuroendocrine Non-Neuroendocrine Neoplasms (MiNEN)
Introduction: Mixed neuroendocrine non-neuroendocrine neoplasms (MiNEN) have been newly defined in the WHO 2017 classification. They are rare tumors, commonly treated in analogy to their non-neuroendocrine (nNE) or neuroendocrine (NE) component without systematic data regarding the optimal therapeutic strategy.
Conference: 15th Annual ENETS conference (2018)
Category: Epidemiology/Natural history/Prognosis- Registries, nationwide and regional surveys
Presenting Author: Dr. med. Leonidas Apostolidis
#777 Laparoscopic Surgery of Functioning Neuroendocrine Tumors of Pancreas
Introduction: Laparoscopic surgery is a feasible technique for benign pancreatic pathologies and has been increasingly reported for neuroendocrine tumors of the pancreas.
Conference: 10th Annual ENETS Conference (2013)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Dr Viktor Shkarban
#1087 Gastro-Entero-Pancreatic Mixed Adenoneuroendocrine Tumors. Report of Four Cases.
Introduction: Mixed adenoneuroendocrine carcinomas (MANECs) is an uncommon entity with ill-defined clinicopathologic characteristics.
Conference: 12th Annual ENETS Conference (2015)
Category: Pathology, grading, staging
Presenting Author: Georgia Karayannopoulou
#2082 Evaluation of Everolimus (EVE) in Patients with Metastatic Lung Neuroendocrine Tumors
Introduction: Lung neuroendocrine tumors are rare, but their incidence has been steadily increasing in recent years.
Conference: 15th Annual ENETS conference (2018)
Category: Medical treatment -Targeted therapies
Presenting Author: Anna Kuznetsova